Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00193479
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Conditions
- Leukemia, Promyelocytic, Acute
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 80
- Registration Number
- NCT00180128
- Locations
- 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 50
- Registration Number
- NCT00169208
- Locations
- 🇫🇷
Service d'Hématologie Hôpital St Louis, Paris, France
🇫🇷Service de médecine D - Maladies du Sang CHU Angers, Angers, France
🇫🇷Service d'hématologie Institut Paoli Calmette, Marseille, France
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 500
- Registration Number
- NCT00151255
- Locations
- 🇦🇹
Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇩🇪Medical Department I, Hospital of Bremen-Mitte, Bremen, Germany
🇩🇪Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden, Essen, Germany
Study Evaluating Mitoxantrone in Multiple Sclerosis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 336
- Registration Number
- NCT00146159
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 95
- Registration Number
- NCT00143975
- Locations
- 🇦🇹
St. Johann Hospital, Clinical Center of Salzburg, Salzburg, Austria
🇩🇪Department of Hematology, Hemostaseology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Medical Department II, City Hospital Karlsruhe gGmbH, Karlsruhe, Germany
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00119730
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicinDrug: dexamethasoneDrug: doxorubicinDrug: leucovorinDrug: mercaptopurineDrug: methotrexateDrug: mitoxantroneDrug: AsparaginaseDrug: prednisoneDrug: thioguanineDrug: vincristineRadiation: radiation therapyDrug: allopurinolDrug: bactrim
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 79
- Registration Number
- NCT00109837
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Minor and James Medical, PLLC, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.